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1.  H1N1 Novel Influenza
As a member of orthomyxoviridae family, influenza viruses are enveloped 
viruses containing eight RNA segments. The main antigenic determinants of 
influenza A and B viruses are two surface glycoproteins, the hemagglutinin 
(H) and the neuraminidase (N). A genetic reassortment between influenza 
A viruses from different animal hosts may lead to an antigenic shift and 
thereby increase the risk of a potential pandemic.
H1N1 and H3N2 subtypes of influenza A have been circulating all over the 
world as seasonal influenza since the last H3N2 pandemic in 1968.1 In April 
2009, the Centers for Disease Control and Prevention of the United States 
identified two cases of human infection with the H1N1 novel influenza 
virus. The greatest initial burden of critical illness and deaths occurred in 
Mexico between March and June 2009.
The virus is a triple-reassortant containing gene segments from swine 
influenza virus, human influenza virus, and avian influenza virus. Genes for 
hemagglutinin and neuraminidase come from swine influenza virus.2 On 
June 11th, 2009, the World Health Organization raised the level of influ-
enza A (H1N1) pandemic alert from phase 5 to 6, as sustained community-
level transmission of the virus is taking place in more than one region of 
the world.
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2.  Case Definition
The diagnosis of influenza-like illness should meet 
the following two criteria: (1) sudden onset of fever 
(tympanic temperature ≥ 38ºC) and respiratory 
tract symptoms; (2) at least one of the following 
symptoms: muscle aches, headache, extreme fa-
tigue, or poor activity in children.
Many respiratory pathogens other than influenza 
virus may cause an illness indistinguishable from 
influenza in children, particularly in younger chil-
dren. A contact history, including the presence of 
influenza-like illness or a laboratory-confirmed in-
fluenza infection in other family members or class-
mates, is an important clue for the diagnosis of 
influenza in young children. It should be noted that 
vomiting and diarrhea are not uncommon in chil-
dren with seasonal influenza or H1N1 novel influ-
enza virus infection.3−5 Without laboratory testing, 
illness caused by H1N1 novel influenza virus can-
not be differentiated from one caused by seasonal 
influenza virus.
3.  Severe Complication
H1N1 novel influenza with severe complication 
should be reported to the Center for Disease Con-
trol of Taiwan within one week, including patients 
with any of the following conditions: (1) pulmonary 
complication that requires hospitalization; (2) neu-
rological complication; (3) myocarditis or pericar-
ditis; (4) invasive bacterial infection; (5) needs for 
intensive care or death.
4.  Risk Factors
Risk factors for severe influenza infection include 
children ≤ 5 years, adults ≥ 65 years, pregnant 
women, those with underlying disorders (including 
abnormal neurological and neurodevelopmental con-
ditions, chronic lung diseases, heart diseases, he-
matological disorders, endocrine disorders, kidney 
disorders, liver disorders, metabolic disorders and 
immunocompromised conditions), and obesity (body 
weight ≥ 95th percentile of the normal range).
Among the 39 pediatric deaths associated with 
H1N1 novel influenza infection in the United States, 
24 (67%) had at least one high-risk medical condi-
tion.6 Among the 24 children with high-risk medi-
cal conditions, 22 (92%) had neurodevelopmental 
conditions (e.g., developmental delay or cerebral 
palsy).6 Among the first 100 hospitalized patients 
with H1N1 novel influenza infection reported to 
Center for Disease Control of Taiwan, 38% had at 
least one risk factor.5
5.  Warning Signs
In children, the appearance of the following signs 
should alert families and their physicians that the 
illness may be deteriorating and the patient needs 
immediate medical attention:7
  1.  Tachypnea: The respiratory rate at resting and 
afebrile conditions exceeds the upper limits 
listed in Table 1.
  2.  Dyspnea
  3.  Chest wall retractions when afebrile
  4.  Cyanosis
  5.  Blood-streaked sputum
  6.  Chest pain or abdominal pain
  7.  Exercise intolerance
  8.  Severe or persistent vomiting
  9.  Not waking up or not interacting
10.  Being so irritable that the child does not want 
to be held
11.  Poor oral intake with signs of dehydration, in-
cluding decreased urine output or having no 
tears when crying
12.  Flu-like symptoms that improve but returning 
with fever and worse cough
13.  Fever with a rash
14.  Changes in level of consciousness or other ab-
normal neurological signs
15.  Persistent fever beyond 72 hours
Pneumonia, including viral pneumonia caused by 
novel influenza virus per se and secondary bacte-
rial pneumonia, is the most common complication 
of severe infections.5,6 Encephalitis is more com-
mon in children with seasonal influenza infections 
than in adults with the same conditions;8 this may 
also be true for H1N1 novel influenza. Laboratory 
test results of severe infections frequently show 
the presence of lymphopenia and elevated creat-
ine phosphokinase levels.5,9
6.  Laboratory Diagnosis
Viral culture and reverse transcriptase-polymerase 
chain reaction (RT-PCR) can reliably identify the 
Table 1  Upper limits of normal respiratory rate in 
children
Age
 Upper limits of normal respiratory
 rate per minute
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presence of H1N1 novel influenza virus in speci-
mens, especially with RT-PCR which has the high-
est sensitivity and specificity. Rapid screening tests 
for influenza may detect the presence of antigen 
from either influenza A or influenza B in respira-
tory specimens. Although rapid screening tests 
have a high specificity (> 95%), their sensitivities 
are variable, ranging from 10% to 70% for detect-
ing H1N1 novel influenza when compared with RT-
PCR. A negative result from a screening test does 
not rule out influenza virus infection.5,7 Screening 
tests cannot distinguish H1N1 novel influenza from 
seasonal H1N1 or H3N2 influenza A viruses.
In general, sputum has the highest concentration 
of virus and should be the most appropriate speci-
men for virus detection. For patients without avail-
able sputum, nasopharyngeal swab should be used 
for virological tests, including the rapid screening 
test. Nasal swab and oropharyngeal swab may be 
associated with a lower sensitivity for virus detec-
tion, however.
For all suspected influenza patients with severe 
complication, appropriate specimens should be sent 
for viral culture and RT-PCR. Rapid screening test 
for influenza may be considered in patients with 
influenza-like illness as defined previously. Patients 
with influenza-like illness should be managed as 
cases of novel influenza infection if their close con-
tacts have been confirmed to have influenza A or 
H1N1 novel influenza infection by any laboratory 
test within one week before or after the onset of 
illness in the patient.
7.  Antiviral Treatment
When a decision is made to use antiviral agents 
for severe infections, treatment should be initi-
ated as soon as possible without waiting for the 
test results. H1N1 novel influenza virus is resistant 
to adamantanes, including amantadine and riman-
tadine. Neuraminidase inhibitors, including osel-
tamivir (Tamiflu) and zanamivir (Relenza), are active 
against H1N1 novel influenza virus.10 Ose ltamivir 
is approved for use in patients 1-year of age and 
older, and who have been symptomatic for no more 
than 2 days. Through the process of Emergency Use 
Authorization, it can be used in infants younger than 
1-year of age and with suspected or confirmed H1N1 
novel influenza infection (Table 2).7
Zanamivir is formulated for oral inhalation and 
approved for the treatment of influenza in patients 
7 years of age and older. The recommended dosage 
is 10 mg (two 5-mg inhalations) twice daily. How-
ever, this inhaled agent is not the treatment of 
choice for severe influenza infection because it can-
not achieve an effective systemic concentration.
Antiviral agents should be given as soon as pos-
sible to achieve the greatest therapeutic effect. 
Although they may be given to patients with mani-
festations of active infection beyond 2 days of ill-
ness, their use may not be necessary at this point 
if any existing fever has subsided for more than 24 
hours, and there is no observable warning sign or 
complication.
The recommended duration of standard treat-
ment is 5 days. Hospitalized patients with severe 
complications may require longer treatment courses 
of up to 10 days. For patients with impaired gas-
trointestinal function and severe illness, the dose 
of oseltamivir may be doubled. Intravenous antivi-
ral agents, if available, may also be considered.
Oseltamivir-resistant H1N1 novel influenza virus 
has been described all over the world, including in 
Taiwan.11,12 Most of these resistant strains emerged 
after the initiation of oseltamivir therapy and are 
limited in their transmissibility.
Oseltamivir may be given to patients with 
influenza-like illness with one of the following 
conditions:
1.  A positive result for influenza A or H1N1 novel 
influenza by rapid screening test, RT-PCR, or 
virus culture;
2.  Close contacts having been confirmed to have 
influenza A virus or H1N1 novel influenza in-
fection by any laboratory test within one week 
before or after the onset of illness in the 
patient;
3.  Having risk factors, as defined previously, dur-
ing influenza pandemic stage;
4.  Having any of the severe complications as 
defined previously.
8.  Other Treatment
Approximately 30−40% of fatal cases with H1N1 novel 
influenza infection have a bacterial coinfection. 
Table 2  Recommended dosage of oseltamivir in 
children
Age and body weight Dosage
≥ 12 mo
  ≤ 15 kg 30 mg twice daily
  16−23 kg 45 mg twice daily
  24−40 kg  60 mg twice daily
  > 40 kg  75 mg twice daily
< 12 mo
  < 3 mo 12 mg twice daily
  3−5 mo 20 mg twice daily
  6−11 mo 25 mg twice daily
4 P.I. Lee et al
The most common pathogens are Streptococcus 
pneumoniae and Staphylococcus aureus.6 Chest 
X-ray findings cannot reliably differentiate between 
severe influenza pneumonia and secondary bac-
terial pneumonia. Pneumonic patches and consol-
idations are commonly seen in both conditions. 
Antibiotics that are effective against S. pneumoniae 
and S. aureus may be given empirically to patients 
with a severe pneumonia. Antibiotics should not 
be used in patients without complication.
The use of high-dose steroid may compromise the 
immune function. Intravenous immune globulin may 
increase the work load of the heart without apparent 
therapeutic effect. Thus, high-dose steroid and in-
travenous immune globulin are not recommended 
in acute phase of H1N1 novel influenza infection.
Oxygen supplement may be given when the 
arterial oxygen saturation is below 92%. Nebuliza-
tion therapy and noninvasive respirator (such as 
continuous positive airway pressure) should be 
avoided in the acute phase to minimize the risk 
of nosocomial transmission. Mechanical ventilator 
and extracorporeal membrane oxygenation may be 
used when necessary.
9.  Immunization
H1N1 novel influenza vaccines available in Taiwan 
are inactivated split-product influenza vaccines 
containing mainly hemagglutinin and neuramini-
dase derived from culture of vaccine virus in chicken 
embryo. For children aged between 6 months and 
9 years, two doses of vaccine with an interval of 
at least 28 days are necessary to mount an ad-
equate immune response. For children 10 years 
and older, one dose of vaccine may induce a sa-
tisfactory immune response. Major adverse events 
include pain, swelling and erythema of injection 
site. The incidence of fever after vaccination is 
about 1−2%.
The H1N1 novel influenza vaccine is contraindi-
cated in children with an allergic history to chicken 
egg, vaccine component, or any kind of influenza 
vaccines, and children with acute illness. Occur-
rence of serious adverse events after vaccination 
should be reported to the Center for Disease 
Control of Taiwan.
10.  Infection Control
Influenza viruses are transmitted from person 
to person primarily through droplet transmission 
and contact with infected respiratory secretions. 
Maintaining good hand hygiene and wearing face-
masks (when necessary) may decrease the risk of 
transmission. The incubation period for influenza 
ranges from 0.5 to 4 days with an average of 2 days. 
Virus shedding begins from 24 hours before illness 
onset and can persist for at least 5 to 7 days. Some 
infected cases may shed virus for longer periods, 
particularly young children, immunocompromized 
persons and patients with severe complication. 
People with influenza-like illness should stay home 
until at least 24 hours after they are free of fever 
(ear or rectal temperature < 38ºC). Hospitalized pa-
tients require an exclusion period of at least 7 days 
from symptom onset and having been afebrile for 
at least 24 hours.
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